Available Technology
Synthetic route for anti-angiogenic natural products cortistatins and analogs
Technology:
A convergent synthetic route for the production of cortistatin at multi-gram level
Markets Addressed
Abnormal angiogenesis has been found to be involved in multiple diseases, such as cancer, macular degeneration and rheumatoid arthritis. Currently, anti-angiogenesis drugs are mainly developed for cancer treatment. In 2010, there are an estimated 24.6 million people in the world living with cancer. Cancer is responsible for 25% of all deaths in the United States and 13% worldwide.The targeted cancer drug market will double in value, from $25 billion in 2008 to $51 billion in 2015. Angiogenesis inhibitor has about 20% of the market currently. Cortistatins, which are isolated from the marine sponge Corticium simplex, have been shown as potent angiogenesis inhibitors. However, isolation of cortistatins from the natural source is impractical for large scale production.
Innovations and Advantages
Chemists in the Myers and Shair laboratories have developed a method to synthesize cortistatins and analogs at a multi-gram level. A synthetic route that provides a compound considered to be the core of the cortistatins has been developed. This core could be used to produce natural and artificial cortistatins, as well as cortistatins tagged with markers for use in target identification experiments. These compounds may be used to screen biological activity toward angiogenesis inhibition and study the relationship between the molecular structure and inhibition activities. This research can lead to better designs of angiogenesis inhibitors for cancer treatment.
Additional Information
Intellectual Property Status: Patent pending.
Tweet
Inventor(s):
Flyer, Alec Nathanson
Lee, Hong Myung
Myers, Andrew G.
Nieto-Oberhuber, Cristina Montserrat
Shair, Matthew D.
Si, Chong
Categories:
- Drug Discovery Tools
- Microbiology/Infectious Diseases
- Oncology
- Ophthalmology
- Small Molecule Therapeutics
- Specialty Chemicals/Chemistry
For further information, please contact:
Vivian Berlin, Director of Business Development
(617) 496-0474
Reference Harvard Case #3219